Private Placement

vTv Therapeutics shores up its finances with a deal worth up to $135M, sharpening its focus on a breakthrough Type 1 diabetes drug, cadisegliatin.

Ensem Therapeutics expands its global trial for ETX-636, a next-gen cancer drug designed to avoid common toxicities, into China's vast patient market.

With a major Phase 3 trial now in Europe, Crystalys Therapeutics aims to fill a critical gap in gout care with a drug already proven in Asian markets.

With an extra $3M, Aduro Clean Technologies advances its game-changing plant, turning investor confidence into a reality for recycling and energy.

NurExone appoints Eyal Gabbai, a healthcare and finance heavyweight, to its board, signaling a strategic pivot from R&D to market execution for its therapies.

Shane Kovacs's exit from Olema Oncology introduces leadership questions as the biotech firm nears a pivotal data readout for its lead breast cancer drug.

Legendary investor Eric Sprott injects $40M into Highlander Silver, fueling its world-class San Luis project and signaling a major move in the silver market.

Asante Gold boosts its war chest with a C$13.8M private placement led by its own chairman, fueling aggressive expansion at its Ghanaian gold mines.

Known for luxury hotels and cigars, Zaya Younan is now building one of California's largest solar plants. A visionary pivot or a high-stakes gamble?

Incheon National University develops a high-performance, eco-friendly gas sensor that dissolves in seawater, tackling both e-waste and air quality issues.

Known for non-opioid pain relief, Scilex is diversifying with a major investment in a stealthy diagnostic firm, hinting at a new data-driven strategy.

Data center giant GDS Holdings lands a $300M investment from a top Chinese firm, fueling expansion and signaling a strategic shift toward national control.

IperionX's Virginia facility is now fully operational, backed by major DoD funding to reshape the US titanium and critical minerals supply chain.

CIRM's new RAPID program aims to revolutionize genetic therapy, using scalable platforms to bring hope to millions with rare diseases who have no options.

A $10M investment from pharma giant Dr. Reddy’s validates Coya Therapeutics' novel ALS drug, funding the path to commercial-scale manufacturing.

The market for drugs like Ozempic and Wegovy is set to explode, fueled by new oral pills, expanded uses for heart and liver disease, and fierce competition.

AI firm Brand Engagement Network shores up its balance sheet with new funding and debt repayment, but a volatile market responds with a sharp stock decline.

As Strawberry Fields REIT preps its year-end report, investors watch for clues on its growth strategy amid industry-wide shifts and looming challenges.

India launches IAIRO, a national AI institute aiming to replicate ISRO's success, moving beyond LLM hype to build its own sovereign AI capabilities.

A new FPS, 'The Defiant,' shifts the focus from Europe to China's brutal War of Resistance, promising historical authenticity and a fresh narrative.